## John D Roache

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5750974/publications.pdf

Version: 2024-02-01

137 papers

5,904 citations

39 h-index 71 g-index

142 all docs

 $\begin{array}{c} 142 \\ \\ \text{docs citations} \end{array}$ 

142 times ranked

4219 citing authors

#	Article	IF	CITATIONS
1	Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial. Neuropsychopharmacology, 2022, 47, 1574-1581.	2.8	41
2	In-office, in-home, and telehealth cognitive processing therapy for posttraumatic stress disorder in veterans: a randomized clinical trial. BMC Psychiatry, 2022, 22, 41.	1.1	15
3	Testing the role of aerobic exercise in the treatment of posttraumatic stress disorder (PTSD) symptoms in U.S. active duty military personnel: a pilot study. Cognitive Behaviour Therapy, 2022, 51, 309-325.	1.9	3
4	Aggression and violent behavior in the military: Self-reported conflict tactics in a sample of service members and veterans seeking treatment for posttraumatic stress disorder. Aggression and Violent Behavior, 2022, 66, 101734.	1.2	3
5	The associations between posttraumatic stress disorder and delay discounting, future orientation, and reward availability: A behavioral economic model. Journal of Traumatic Stress, 2022, , .	1.0	2
6	Quetiapine as an adjunct to enhance engagement in prolonged exposure therapy for PTSD in veterans: A randomized, pilot trial. Journal of Behavioral and Cognitive Therapy, 2022, 32, 243-253.	0.7	2
7	Social Support and the Rehabilitation of Alcohol-Impaired Drivers: Drinking Motives as Moderators. Health Communication, 2021, 36, 540-550.	1.8	3
8	A Comparison of Cognitive Processing Therapy and Seeking Safety for the Treatment of Posttraumatic Stress Disorder in Veterans. Psychiatric Quarterly, 2021, 92, 735-750.	1.1	2
9	The Impact of Hazardous Drinking Among Active Duty Military With Posttraumatic Stress Disorder: Does Cognitive Processing Therapy Format Matter?. Journal of Traumatic Stress, 2021, 34, 210-220.	1.0	4
10	STRONG STAR and the Consortium to Alleviate PTSD: Shaping the future of combat PTSD and related conditions in military and veteran populations. Contemporary Clinical Trials, 2021, 110, 106583.	0.8	15
11	Is extended release naltrexone superior to buprenorphineâ€naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial. Alcoholism: Clinical and Experimental Research, 2021, 45, 2569-2578.	1.4	3
12	The Role(s) of Psychopharmacology in the Treatment of PTSD., 2021,,.		0
13	Intensive, Multi-Couple Group Therapy for PTSD: A Nonrandomized Pilot Study With Military and Veteran Dyads. Behavior Therapy, 2020, 51, 700-714.	1.3	23
14	Quetiapine augmentation of prolonged exposure therapy in veterans with PTSD and a history of mild traumatic brain injury: design and methodology of a pilot study. Military Medical Research, 2020, 7, 46.	1.9	4
15	Manage Emotions to Reduce Aggression. Journal of Nervous and Mental Disease, 2020, 208, 897-903.	0.5	3
16	Predictors of Cognitive Behavioral Therapy for Insomnia (CBTi) Outcomes in Active-Duty U.S. Army Personnel. Behavior Therapy, 2020, 51, 522-534.	1.3	9
17	Sleep problems in active duty military personnel seeking treatment for posttraumatic stress disorder: presence, change, and impact on outcomes. Sleep, 2020, 43, .	0.6	27
18	Isradipine enhancement of virtual reality cue exposure for smoking cessation: Rationale and study protocol for a double-blind randomized controlled trial. Contemporary Clinical Trials, 2020, 94, 106013.	0.8	6

#	Article	IF	Citations
19	Continuous Ketamine Infusion for Pain as an Opportunity for Psychotherapy for PTSD: A Case Series of Ketamine-Enhanced Psychotherapy for PTSD and Pain (KEP-P2). Psychotherapy and Psychosomatics, 2020, 89, 326-329.	4.0	15
20	A pilot randomized controlled trial of cognitive behavioral treatment for trauma-related nightmares in active duty military personnel. Journal of Clinical Sleep Medicine, 2020, 16, 29-40.	1.4	11
21	Enhancing Access to Psychiatric Care for Posttraumatic Stress Disorder in Veterans with Mild Traumatic Brain Injury through Integrated Services. Psychiatric Quarterly, 2019, 90, 815-827.	1.1	10
22	Mediation of suicide ideation in prolonged exposure therapy for posttraumatic stress disorder. Behaviour Research and Therapy, 2019, 119, 103409.	1.6	10
23	Reduced Salience and Enhanced Central Executive Connectivity Following PTSD Treatment. Chronic Stress, 2019, 3, 247054701983897.	1.7	26
24	Salience Network Disruption in U.S. Army Soldiers With Posttraumatic Stress Disorder. Chronic Stress, 2019, 3, 247054701985046.	1.7	29
25	Enhancing Completion of Cognitive Processing Therapy for Posttraumatic Stress Disorder with Quetiapine in Veterans with Mild Traumatic Brain Injury: a Case Series. Psychiatric Quarterly, 2019, 90, 431-445.	1.1	11
26	Repeated ketamine infusions for antidepressant-resistant PTSD: Methods of a multicenter, randomized, placebo-controlled clinical trial. Contemporary Clinical Trials, 2019, 81, 11-18.	0.8	26
27	Phosphatidylethanol Homologs in Blood as Biomarkers for the Time Frame and Amount of Recent Alcohol Consumption., 2019,, 567-576.		3
28	Examination of Treatment Effects on Hazardous Drinking Among Service Members With Posttraumatic Stress Disorder. Journal of Traumatic Stress, 2019, 32, 310-316.	1.0	8
29	Estimating resource utilization demands in implementing statewide screening, brief intervention, and referral to treatment for alcohol-impaired drivers. Traffic Injury Prevention, 2019, 20, 15-22.	0.6	2
30	Does prolonged exposure increase suicide risk? Results from an active duty military sample. Behaviour Research and Therapy, 2019, 118, 87-93.	1.6	23
31	Processing transdermal alcohol concentration (TAC) data to detect low-level drinking. Alcohol, 2019, 81, 101-110.	0.8	28
32	The Role of Social Support in Motivating Reductions in Alcohol Use: A Test of Three Models of Social Support in Alcoholâ€Impaired Drivers. Alcoholism: Clinical and Experimental Research, 2019, 43, 123-134.	1.4	13
33	The pattern of symptom change during prolonged exposure therapy and present-centered therapy for PTSD in active duty military personnel. Psychological Medicine, 2019, 49, 1980-1989.	2.7	14
34	Caffeine Use in Military Personnel With PTSD: Prevalence and Impact on Sleep. Behavioral Sleep Medicine, 2019, 17, 202-212.	1,1	6
35	Patterns and predictors of change in trauma-focused treatments for war-related posttraumatic stress disorder Journal of Consulting and Clinical Psychology, 2019, 87, 1019-1029.	1.6	20
36	Impact of cognitive behavioral therapy for insomnia disorder on sleep and comorbid symptoms in military personnel: a randomized clinical trial. Sleep, 2018, 41, .	0.6	34

#	Article	IF	CITATIONS
37	Differences in the Synthesis and Elimination of Phosphatidylethanol 16:0/18:1 and 16:0/18:2 After Acute Doses of Alcohol. Alcoholism: Clinical and Experimental Research, 2018, 42, 851-860.	1.4	51
38	Translating transdermal alcohol monitoring procedures for contingency management among adults recently arrested for DWI. Addictive Behaviors, 2018, 83, 56-63.	1.7	19
39	Effect of Prolonged Exposure Therapy Delivered Over 2 Weeks vs 8 Weeks vs Present-Centered Therapy on PTSD Symptom Severity in Military Personnel. JAMA - Journal of the American Medical Association, 2018, 319, 354.	3.8	252
40	Factor Structure and Psychometric Properties of the Peritraumatic and Posttraumatic Emotions Questionnaires Among Active Duty Military Personnel With Posttraumatic Stress Disorder. Journal of Traumatic Stress, 2018, 31, 826-836.	1.0	1
41	Design of a clinical effectiveness trial of in-home cognitive processing therapy for combat-related PTSD. Contemporary Clinical Trials, 2018, 73, 27-35.	0.8	8
42	Doxazosin for the treatment of co-occurring PTSD and alcohol use disorder: Design and methodology of a randomized controlled trial in military veterans. Contemporary Clinical Trials, 2018, 73, 8-15.	0.8	11
43	The correspondence between transdermal alcohol monitoring and daily self-reported alcohol consumption. Addictive Behaviors, 2018, 85, 147-152.	1.7	24
44	Pharmacokinetics of Phosphatidylethanol 16:0/20:4 in Human Blood After Alcohol Intake. Alcoholism: Clinical and Experimental Research, 2018, 42, 2094-2099.	1.4	18
45	Intensive prolonged exposure therapy for combat-related posttraumatic stress disorder: Design and methodology of a randomized clinical trial. Contemporary Clinical Trials, 2018, 72, 126-136.	0.8	12
46	Effect of Group vs Individual Cognitive Processing Therapy in Active-Duty Military Seeking Treatment for Posttraumatic Stress Disorder. JAMA Psychiatry, 2017, 74, 28.	6.0	225
47	Time Delays in Transdermal Alcohol Concentrations Relative to Breath Alcohol Concentrations. Alcohol and Alcoholism, 2017, 52, 35-41.	0.9	49
48	Moving effective treatment for posttraumatic stress disorder to primary care: A randomized controlled trial with active duty military Families, Systems and Health, 2017, 35, 450-462.	0.4	57
49	Behavioral Impulsivity Does Not Predict Naturalistic Alcohol Consumption or Treatment Outcomes. Addictive Disorders and Their Treatment, 2016, 15, 120-128.	0.5	2
50	Characterization of the Pharmacokinetics of Phosphatidylethanol 16:0/18:1 and 16:0/18:2 in Human Whole Blood After Alcohol Consumption in a Clinical Laboratory Study. Alcoholism: Clinical and Experimental Research, 2016, 40, 1228-1234.	1.4	75
51	Qualitative examination of cognitive change during PTSD treatment for active duty service members. Behaviour Research and Therapy, 2016, 79, 1-6.	1.6	22
52	Effects of tryptophan depletion and a simulated alcohol binge on impulsivity Experimental and Clinical Psychopharmacology, 2015, 23, 109-121.	1.3	25
53	A randomized clinical trial of group cognitive processing therapy compared with group present-centered therapy for PTSD among active duty military personnel Journal of Consulting and Clinical Psychology, 2015, 83, 1058-1068.	1.6	188
54	Using Transdermal Alcohol Monitoring to Detect Low‣evel Drinking. Alcoholism: Clinical and Experimental Research, 2015, 39, 1120-1127.	1.4	42

#	Article	IF	Citations
55	The Potential Clinical Utility of Transdermal Alcohol Monitoring Data to Estimate the Number of Alcoholic Drinks Consumed. Addictive Disorders and Their Treatment, 2015, 14, 124-130.	0.5	22
56	Assessing the Validity of Participant-Derived Compared to Staff-Derived Values to Compute a Binge Score. Alcohol and Alcoholism, 2015, 50, 413-419.	0.9	3
57	Transdermal alcohol concentration data collected during a contingency management program to reduce at-risk drinking. Drug and Alcohol Dependence, 2015, 148, 77-84.	1.6	50
58	Bupropion for the treatment of methamphetamine dependence in non-daily users: A randomized, double-blind, placebo-controlled trial. Drug and Alcohol Dependence, 2015, 150, 170-174.	1.6	54
59	Using Contingency Management Procedures to Reduce At-Risk Drinking in Heavy Drinkers. Alcoholism: Clinical and Experimental Research, 2015, 39, 743-751.	1.4	34
60	Accounting for sex-related differences in the estimation of breath alcohol concentrations using transdermal alcohol monitoring. Psychopharmacology, 2015, 232, 115-123.	1.5	39
61	Do Variable Rates of Alcohol Drinking Alter the Ability to Use Transdermal Alcohol Monitors to Estimate Peak Breath Alcohol and Total Number of Drinks?. Alcoholism: Clinical and Experimental Research, 2014, 38, 2517-2522.	1.4	28
62	Use of continuous transdermal alcohol monitoring during a contingency management procedure to reduce excessive alcohol use. Drug and Alcohol Dependence, 2014, 142, 301-306.	1.6	77
63	The need for expanded monitoring of adverse events in behavioral health clinical trials. Contemporary Clinical Trials, 2013, 34, 152-154.	0.8	48
64	A Multisite, Double-blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Vigabatrin for Treating Cocaine Dependence. JAMA Psychiatry, 2013, 70, 630.	6.0	36
65	Topiramate's effects on cocaineâ€induced subjective mood, craving and preference for money over drug taking. Addiction Biology, 2013, 18, 405-416.	1.4	21
66	From Free to Free Market: Cost Recovery in Federally Funded Clinical Research. Science Translational Medicine, 2012, 4, 141cm7.	5.8	4
67	Preliminary Evidence for cue-induced Alcohol Craving Modulated by Serotonin Transporter Gene Polymorphism rs1042173. Frontiers in Psychiatry, 2012, 3, 6.	1.3	61
68	Commentary on Comparison of Alcoholism Subtypes as Moderators of the Response to Sertraline Treatment. Alcoholism: Clinical and Experimental Research, 2012, 36, 561-563.	1.4	3
69	A double-blind, placebo-controlled assessment of the safety of potential interactions between intravenous cocaine, ethanol, and oral disulfiram. Drug and Alcohol Dependence, 2011, 119, 37-45.	1.6	19
70	Pharmacogenetic Approach at the Serotonin Transporter Gene as a Method of Reducing the Severity of Alcohol Drinking. American Journal of Psychiatry, 2011, 168, 265-275.	4.0	180
71	Role of the Human Laboratory in the Development of Medications for Alcohol and Drug Dependence. , 2010, , 129-157.		2
72	Can Serotonin Transporter Genotype Predict Craving in Alcoholism?. Alcoholism: Clinical and Experimental Research, 2009, 33, 1329-1335.	1.4	28

#	Article	IF	Citations
73	Modafinil for the treatment of cocaine dependence. Drug and Alcohol Dependence, 2009, 104, 133-139.	1.6	193
74	Benefits of Topiramate Treatment in a Dual-Diagnosis Patient. Psychosomatics, 2009, 50, 426-427.	2.5	6
75	Drinking Histories in Alcohol-Use-Disordered Youth: Preliminary Findings on Relationships to Platelet Serotonin Transporter Expression With Genotypes of the Serotonin Transporter. Journal of Studies on Alcohol and Drugs, 2009, 70, 899-907.	0.6	8
76	Prediction of Serotonergic Treatment Efficacy Using Age of Onset and Type A/B Typologies of Alcoholism. Alcoholism: Clinical and Experimental Research, 2008, 32, 1502-1512.	1.4	50
77	Can serotonin transporter genotype predict serotonergic function, chronicity, and severity of drinking?. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 209-216.	2.5	36
78	Neurosteroids in Alcohol and Substance Use. , 2008, , 509-538.		1
79	Relative Abuse Liability of Indiplon and Triazolam in Humans: A Comparison of Psychomotor, Subjective, and Cognitive Effects. Journal of Pharmacology and Experimental Therapeutics, 2007, 322, 749-759.	1.3	16
80	Effects of acute topiramate dosing on methamphetamine-induced subjective mood. International Journal of Neuropsychopharmacology, 2007, 10, 85.	1.0	47
81	Effects of topiramate on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition in recently abstinent methamphetamine-dependent individuals. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 123-130.	2.5	33
82	Kinetic and cardiovascular effects of acute topiramate dosing among non-treatment-seeking, methamphetamine-dependent individuals. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 455-461.	2.5	10
83	A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of cocaine dependence. Drug and Alcohol Dependence, 2006, 84, 256-263.	1.6	65
84	Bupropion Reduces Methamphetamine-Induced Subjective Effects and Cue-Induced Craving. Neuropsychopharmacology, 2006, 31, 1537-1544.	2.8	141
85	Effects of isradipine, a dihydropyridine-class calcium-channel antagonist, on d-methamphetamine's subjective and reinforcing effects. International Journal of Neuropsychopharmacology, 2005, 8, 203-213.	1.0	17
86	Effects of isradipine on cocaine-induced changes in cognitive performance in recently abstinent cocaine-dependent individuals. International Journal of Neuropsychopharmacology, 2005, 8, 549.	1.0	16
87	Behavioral Inhibition and Activation in Posttraumatic Stress Disorder. Journal of Nervous and Mental Disease, 2005, 193, 102-109.	0.5	67
88	Effects of repeated-dose isradipine on the abuse liability of cocaine Experimental and Clinical Psychopharmacology, 2005, 13, 319-326.	1.3	19
89	Acute Intravenous Low- and High-Dose Cocaine Reduces Quantitative Global and Regional Cerebral Blood Flow in Recently Abstinent Subjects with Cocaine use Disorder. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, 928-936.	2.4	16
90	Emerging Biomarkers: New Directions and Clinical Applications. Alcoholism: Clinical and Experimental Research, 2005, 29, 465-473.	1.4	46

#	Article	IF	CITATIONS
91	Effects of isradipine on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition. Psychopharmacology, 2005, 178, 296-302.	1.5	30
92	Safety of intravenous methamphetamine administration during treatment with bupropion. Psychopharmacology, 2005, 182, 426-435.	1.5	58
93	Platelet serotonin uptake and paroxetine binding among allelic genotypes of the serotonin transporter in alcoholics. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2005, 29, 7-13.	2.5	24
94	Kinetic and cardiovascular comparison of immediate-release isradipine and sustained-release isradipine among non-treatment-seeking, cocaine-dependent individuals. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2005, 29, 15-20.	2.5	16
95	Isradipine Decreases the Hemodynamic Response of Cocaine and MethamphetamineResults From Two Human Laboratory Studies. American Journal of Hypertension, 2005, 18, 813-822.	1.0	32
96	Relative Bioavailability of an Extemporaneous Ondansetron 4-mg Capsule Formulation versus Solution. Pharmacotherapy, 2004, 24, 477-481.	1.2	5
97	Treatment Effects of Methylphenidate on Cognitive Functioning in Children With Mental Retardation and ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 2004, 43, 677-685.	0.3	48
98	Effects of Methylphenidate Treatment in Children With Mental Retardation and ADHD: Individual Variation in Medication Response. Journal of the American Academy of Child and Adolescent Psychiatry, 2004, 43, 686-698.	0.3	43
99	Effects of Isradipine on Cocaine-Induced Subjective Mood. Journal of Clinical Psychopharmacology, 2004, 24, 180-191.	0.7	18
100	Treatment Effects of Methylphenidate on Behavioral Adjustment in Children With Mental Retardation and ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 2003, 42, 209-216.	0.3	90
101	Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet, The, 2003, 361, 1677-1685.	6.3	718
102	Dose-Ranging Kinetics and Behavioral Pharmacology of Naltrexone and Acamprosate, Both Alone and Combined, in Alcohol-Dependent Subjects. Journal of Clinical Psychopharmacology, 2003, 23, 281-293.	0.7	61
103	THE ROLE OF ANXIETY IN PREDICTING DRINKING BEHAVIOUR. Alcohol and Alcoholism, 2003, 38, 360-363.	0.9	26
104	Relative reinforcing effects of different benzodiazepine doses for rhesus monkeys. Drug and Alcohol Dependence, 2002, 68, 275-283.	1.6	6
105	Ondansetron reduces the craving of biologically predisposed alcoholics. Psychopharmacology, 2002, 160, 408-413.	1.5	109
106	Combining Ondansetron and Naltrexone Treats Biological Alcoholics: Corroboration of Self-Reported Drinking by Serum Carbohydrate Deficient Transferrin, A Biomarker. Alcoholism: Clinical and Experimental Research, 2001, 25, 847-849.	1.4	26
107	Age of Onset as a Discriminator Between Alcoholic Subtypes in a Treatment-Seeking Outpatient Population. American Journal on Addictions, 2000, 9, 17-27.	1.3	88
108	A ROLE FOR VALPROATE IN THE TREATMENT OF SEDATIVE-HYPNOTIC WITHDRAWAL AND FOR RELAPSE PREVENTION. Alcohol and Alcoholism, 2000, 35, 319-323.	0.9	11

#	Article	IF	CITATIONS
109	Ondansetron for Reduction of Drinking Among Biologically Predisposed Alcoholic Patients. JAMA - Journal of the American Medical Association, 2000, 284, 963.	3.8	385
110	Laboratory Measures of Methylphenidate Effects in Cocaine-Dependent Patients Receiving Treatment. Journal of Clinical Psychopharmacology, 2000, 20, 61-68.	0.7	34
111	Isradipine, a dihydropyridine-class calcium channel antagonist, attenuates some of d -methamphetamine's positive subjective effects: a preliminary study. Psychopharmacology, 1999, 144, 295-300.	1.5	34
112	Excess coffee consumption in simulated complex work settings: Detriment or facilitation of performance?. Journal of Applied Psychology, 1997, 82, 774-782.	4.2	27
113	Ethanol and pentobarbital: Comparison of behavioral and subjective effects in sedative drug abusers Experimental and Clinical Psychopharmacology, 1997, 5, 203-215.	1.3	18
114	Replacement Medication for Cocaine Dependence. Journal of Clinical Psychopharmacology, 1997, 17, 485-488.	0.7	170
115	Diazepam reinforcement in anxious patients Experimental and Clinical Psychopharmacology, 1996, 4, 308-314.	1.3	8
116	Effects of methylphenidate on behavioral adjustment in children with mental retardation and ADHD: Preliminary findings from a study in progress. Journal of Developmental and Physical Disabilities, 1996, 8, 313-333.	1.0	3
117	Effects of Alprazolam on Complex Human Functioning 1. Journal of Applied Social Psychology, 1996, 26, 1912-1930.	1.3	6
118	Alcohol Hangover and Managerial Effectiveness. Alcoholism: Clinical and Experimental Research, 1995, 19, 1141-1146.	1.4	46
119	Findings From Self-Administration Research on the Addiction Potential of Benzodiazepines. Psychiatric Annals, 1995, 25, 153-157.	0.1	31
120	THE EFFECTS OF SMOKED MARIJUANA ON PROGRESSIVE-INTERVAL SCHEDULE PERFORMANCE IN HUMANS. Journal of the Experimental Analysis of Behavior, 1994, 62, 73-87.	0.8	13
121	Alcohol and Complex Functioning1. Journal of Applied Social Psychology, 1993, 23, 847-866.	1.3	23
122	Acute effects of marijuana smoking on aggressive, escape and point-maintained responding of male drug users. Psychopharmacology, 1993, 111, 163-168.	1.5	51
123	Triazolam and ethanol effects on human matching-to-sample performance vary as a function of pattern size and discriminability. Drug and Alcohol Dependence, 1993, 32, 219-229.	1.6	7
124	Effects of alcohol intoxication on risk taking, strategy, and error rate in visuomotor performance Journal of Applied Psychology, 1992, 77, 515-524.	4.2	22
125	Effects of triazolam on human aggressive, escape and point-maintained responding. Pharmacology Biochemistry and Behavior, 1991, 40, 835-839.	1.3	31
126	Performance and physiological measures in abuse liability evaluation. Addiction, 1991, 86, 1595-1600.	1.7	18

#	ARTICLE	IF	CITATIONS
127	The Effects of Codeine on Human Aggressive Responding. International Clinical Psychopharmacology, 1990, 5, 195-204.	0.9	19
128	Dose-Response Evaluation of the Amnestic Effects of. Journal of Clinical Psychopharmacology, 1990, 10, 160???167.	0.7	32
129	Addiction Potential of Benzodiazedpines and Non-Benzodiazepine Anxiolytics. Advances in Alcohol & Substance Abuse, 1990, 9, 103-128.	0.5	6
130	Diazepam and triazolam self-administration in sedative abusers: concordance of subject ratings, performance and drug self-administration. Psychopharmacology, 1989, 99, 309-315.	1.5	34
131	Repeated administration of diazepam and triazolam to subjects with histories of drug abuse. Drug and Alcohol Dependence, 1986, 17, 15-29.	1.6	15
132	Effects of benzodiazepines on taste aversions in a two-bottle choice paradigm. Pharmacology Biochemistry and Behavior, 1986, 25, 431-437.	1.3	9
133	Acute effects of smoking marijuana on hormones, subjective effects and performance in male human subjects. Pharmacology Biochemistry and Behavior, 1986, 24, 1749-1754.	1.3	97
134	Relative abuse liability of triazolam: Experimental assessment in animals and humans. Neuroscience and Biobehavioral Reviews, 1985, 9, 133-151.	2.9	72
135	Abuse Liability of Benzodiazepines: A Review of Human Studies Evaluating Subjective and/or Reinforcing Effects., 1985,, 209-225.		23
136	Relative abuse liability of diazepam and oxazepam: Behavioral and subjective dose effects. Psychopharmacology, 1984, 84, 147-154.	1.5	78
137	5-Hydroxytryptophan-induced conditioned taste aversion to ethanol in the rat. Pharmacology Biochemistry and Behavior, 1983, 18, 785-790.	1.3	47